ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?
Telix Pharmaceuticals (ASX:TLX) is back in focus after a Type B meeting with the U.S. Food and Drug Administration confirmed that safety data from its ProstACT Global Phase 3 trial supports moving TLX591-Tx into Part 2.
See our latest analysis for Telix Pharmaceuticals.
Alongside the FDA update, Telix Pharmaceuticals has drawn fresh attention after a strong 30-day share price return of 36.03% and year to date share price return of 51.23%. However, the 1-year total shareholder return declined...